All In Biotech

Drug Trial Radar · NCT04810637

A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19

A Phase 2, Randomized, Double Blinded, Placebo Controlled, Parallel Group, Single Administration Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19

Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

210

Planned (sponsor's estimate)

Start

Nov 1, 2020

Primary completion

Jun 2021

Study completion Sep 2021

Sponsor

Lead sponsor
PT Kalbe Genexine BiologicsIndustry
Sponsor type
Industry
Collaborators
Genexine, Inc.
First posted
Mar 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 prospective, randomized, placebo-controlled, double-blinded, parallel group, single administration, multi-center study to assess the safety and efficacy of efineptakin alfa single treatment compared to placebo in elderly participants (adults ≥50years) with asymptomatic or mild COVID-19

Conditions

  • Covid19

Interventions

  • GX-I7Drug

    Recombinant human interleukin-7 hybrid Fc

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose findingTime frame: 9 weeks
  2. Absolute lymphocyte count (ALC)Time frame: 9 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mitra Keluarga Kelapa Gading

    Jakarta Pusat, Indonesia · Recruiting

  • Mitra Keluarga Kemayoran

    Jakarta Pusat, Indonesia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.